Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

‘Game changer’: FDA approves first PSMA-targeted PET imaging tracer for men with prostate cancer

Both the University of California, San Francisco, and UCLA received the greenlight for Gallium-68 PSMA-11 and noted it is rare for academic institutions to obtain such approval.

Humana

Imaging experts slam Humana for ‘ill-informed and wrong’ decision to deny coverage for PET/CT exams

The pair said that without hearing a solid argument, they will be "relentless" in opposing the insurance giant's coverage determination. 

insurance payer payment insurer

Top nuclear imaging group ‘strongly disagrees’ with Humana’s decision to refuse coverage for PET/CT

The Society of Nuclear Medicine and Molecular Imaging said the move denies patients access to potentially lifesaving technologies.

FDA expert panel votes against Biogen’s Alzheimer’s drug, dashing latest hopes for treatment

Alzheimer's Association President and CEO Harry Johns said the vote was disappointing, claiming publicly released data on aducanumab justified its federal approval.

FDA grants fast track status to investigational molecular imaging agent

Tokyo-based Astellas's tracer was developed to supplement surgeries and reduces the chance of iatrogenic ureteral injury during colorectal or gynecologic procedures.

Bracco gains FDA approval for new cardiac PET infusion system

This update will replace the company’s existing infusion system and includes new smart features, such as workflow improvements and dosing options.

Health startup RayzeBio nets $45M in funding to advance targeted radiopharmaceuticals in oncology

President and CEO Ken Song, MD, said the radiopharmaceutical field remains an untapped opportunity in cancer care.

Thumbnail

Smart glasses take the neck pain out of fluoroscopic image-guided surgery

Doctors with Murayama Medical Center in Tokyo unveiled their device, which attaches to a normal pair of glasses, in the Journal of Neurosurgery: Spine.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Trimed Popup
Trimed Popup